Raising seed investment to further develop cancer treatment

Danish biotech startup Kripthonite Therapeutics has secured a seed investment from Marigold Maturation Fund. The capital will be used to further develop the company’s hypoxia-targeted macrocycles (HTMCs) technology and bring its lead drug candidate, PH1154, closer to IND-preparation toxicology studies.

“I’m excited to take on the challenge and see if we’re really on our way with a revolutionary treatment for the patients who need it most. Thank you to everyone who has been with us along the way and to the investors who believe in us! Now we’re moving forward,” co-founder Kristian Mark Jacobsen on LinkedIn.

He is co-founder of Kripthonite Therapeutics together with Per Hjerrild and Professor Thomas Poulsen. The startup is spun out of research from the Department of Chemistry at Aarhus University and has shown solid preclinical proof-of-concept. With the support from Marigold, the company strengthens its position in the development of new treatments for patients with hypoxic solid tumors, a cancer type with a large unmet medical need.

“It has taken a long time and a lot of persistence. Now we can finally continue the development of a promising new cancer treatment that we discovered at the Department of Chemistry during my PhD studies with Thomas Poulsen,” Kristian Mark Jacobsen continues.

Indlægget Raising seed investment to further develop cancer treatment blev først udgivet på TechSavvy.